-
As the new kid on the OB/GYN Clinical Alert block, and as the generalist among the editors, I intend to focus on topics that come up commonly in my own practice of obstetrics and gynecology. The beauty of having this format is that cutting edge science can be presented, but also sacred cows can be challenged.
-
-
Moderate levels of activity, including walking, are associated with substantially lower risks of hip fracture in postmenopausal women.
-
Delay in treatment to allow for fetal maturity is safe in patients with early stage I cervical carcinoma associated with pregnancy.
-
A single dose of 1.5-mg levonorgestrel and a single low dose of 10-mg mifepristone are effective methods for emergency contraception.
-
Ventilation/perfusion scanning appears to be safe and effective, at least in ruling out significant clinical pulmonary embolism in pregnant patients. However, prospective studies over longer time periods should be undertaken to validate these conclusions.
-
The FDA has mandated a Black Box warning for all estrogen and estrogen/progestin products for use by postmenopausal women. The new warnings are based on analysis of data from the Womens Health Initiative (WHI) study that was published July 2002.
-
Vessey, Painter, and Yeates from the University of Oxford used the prospective cohort of women enrolled in the Oxford Family Planning Association Study to assess mortality in users and nonusers of oral contraceptives.
-
Compared to histopathology, visual diagnosis of PID is neither accurate nor reproducible.
-
Intraperitoneal chromic phosphate did not decrease the risk of relapse or improve survival for patients with stage III epithelial ovarian cancer after a negative second-look surgery.
